Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trial
Epic Sciences and its research partners report the use of the company's new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC).
The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930).
The Epic Sciences CTC HRD assay measures chromosomal instability within circulating tumor cells in the blood of patients with cancer by identifying distinct cell morphology feature sets. Chromosomal instability, a hallmark of aggressive cancer, has also been associated with DNA Damage Repair (DDR) deficiency.
PARP inhibitors have been shown to be an effective therapeutic in the treatment of cancers characterized by chromosomal instability by targeting DNA repair pathways in cells with DDR deficiency. However, it has been very difficult to measure chromosomal instability from tumor biopsy due to under sampling and heterogeneity, problems designed to be addressed by Epic’s liquid biopsy approach.